81 related articles for article (PubMed ID: 24706342)
1. A Monte Carlo evaluation of dose enhancement by cisplatin and titanocene dichloride chemotherapy drugs in brachytherapy with photon emitting sources.
Yahya Abadi A; Ghorbani M; Mowlavi AA; Knaup C
Australas Phys Eng Sci Med; 2014 Jun; 37(2):327-36. PubMed ID: 24706342
[TBL] [Abstract][Full Text] [Related]
2. Photon activation therapy: a Monte Carlo study on dose enhancement by various sources and activation media.
Bakhshabadi M; Ghorbani M; Meigooni AS
Australas Phys Eng Sci Med; 2013 Sep; 36(3):301-11. PubMed ID: 23934379
[TBL] [Abstract][Full Text] [Related]
3. Dose enhancement by various nanoparticles in prostate brachytherapy.
Ghorbani M; Bakhshabadi M; Golshan A; Knaup C
Australas Phys Eng Sci Med; 2013 Dec; 36(4):431-40. PubMed ID: 24307601
[TBL] [Abstract][Full Text] [Related]
4. A Monte Carlo study on tissue dose enhancement in brachytherapy: a comparison between gadolinium and gold nanoparticles.
Bahreyni Toossi MT; Ghorbani M; Mehrpouyan M; Akbari F; Sobhkhiz Sabet L; Soleimani Meigooni A
Australas Phys Eng Sci Med; 2012 Jun; 35(2):177-85. PubMed ID: 22700179
[TBL] [Abstract][Full Text] [Related]
5. Dose perturbations by high atomic number materials in intravascular brachytherapy.
Nath R; Yue N; Weinberger J
Cardiovasc Radiat Med; 1999; 1(2):144-53. PubMed ID: 11229547
[TBL] [Abstract][Full Text] [Related]
6. Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice.
Friedrich M; Villena-Heinsen C; Farnhammer C; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(4):333-7. PubMed ID: 9744720
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric characterization of an 192Ir brachytherapy source with the Monte Carlo code PENELOPE.
Casado FJ; García-Pareja S; Cenizo E; Mateo B; Bodineau C; Galán P
Phys Med; 2010; 26(3):132-9. PubMed ID: 20034828
[TBL] [Abstract][Full Text] [Related]
8. Simulation study on potential accuracy gains from dual energy CT tissue segmentation for low-energy brachytherapy Monte Carlo dose calculations.
Landry G; Granton PV; Reniers B; Ollers MC; Beaulieu L; Wildberger JE; Verhaegen F
Phys Med Biol; 2011 Oct; 56(19):6257-78. PubMed ID: 21896967
[TBL] [Abstract][Full Text] [Related]
9. Potential for enhancing external beam radiotherapy for lung cancer using high-Z nanoparticles administered via inhalation.
Hao Y; Altundal Y; Moreau M; Sajo E; Kumar R; Ngwa W
Phys Med Biol; 2015 Sep; 60(18):7035-43. PubMed ID: 26309064
[TBL] [Abstract][Full Text] [Related]
10. Dose to tissue medium or water cavities as surrogate for the dose to cell nuclei at brachytherapy photon energies.
Enger SA; Ahnesjö A; Verhaegen F; Beaulieu L
Phys Med Biol; 2012 Jul; 57(14):4489-500. PubMed ID: 22722477
[TBL] [Abstract][Full Text] [Related]
11. Correction factors for source strength determination in HDR brachytherapy using the in-phantom method.
Ubrich F; Wulff J; Engenhart-Cabillic R; Zink K
Z Med Phys; 2014 May; 24(2):138-52. PubMed ID: 24021956
[TBL] [Abstract][Full Text] [Related]
12. Neutron capture therapy: a comparison between dose enhancement of various agents, nanoparticles and chemotherapy drugs.
Khosroabadi M; Ghorbani M; Rahmani F; Knaup C
Australas Phys Eng Sci Med; 2014 Sep; 37(3):541-9. PubMed ID: 24961208
[TBL] [Abstract][Full Text] [Related]
13. Effect of tissue composition on dose distribution in brachytherapy with various photon emitting sources.
Ghorbani M; Salahshour F; Haghparast A; Moghaddas TA; Knaup C
J Contemp Brachytherapy; 2014 Mar; 6(1):54-67. PubMed ID: 24790623
[TBL] [Abstract][Full Text] [Related]
14. Super-selective intra-arterial platinum-based chemotherapy concurrent with low-dose-rate plaque brachytherapy in the treatment of retinoblastoma: A simulation study.
Mostaghimi H; Ahmadabad FG; Rezaei H
J Cancer Res Ther; 2021; 17(1):130-135. PubMed ID: 33723143
[TBL] [Abstract][Full Text] [Related]
15. Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride.
Villena-Heinsen C; Friedrich M; Ertan AK; Farnhammer C; Schmidt W
Anticancer Drugs; 1998 Jul; 9(6):557-63. PubMed ID: 9877245
[TBL] [Abstract][Full Text] [Related]
16. Tumor dose enhancement by nanoparticles during high dose rate (192)Ir brachytherapy.
Zabihzadeh M; Arefian S
J Cancer Res Ther; 2015; 11(4):752-9. PubMed ID: 26881513
[TBL] [Abstract][Full Text] [Related]
17. Study of the IsoAid ADVANTAGE (125)I brachytherapy source dosimetric parameters using Monte Carlo simulation.
Sadeghi M; Hamed Hosseini S
Appl Radiat Isot; 2010 Jan; 68(1):211-3. PubMed ID: 19762248
[TBL] [Abstract][Full Text] [Related]
18. A systematic evaluation of the dose-rate constant determined by photon spectrometry for 21 different models of low-energy photon-emitting brachytherapy sources.
Chen ZJ; Nath R
Phys Med Biol; 2010 Oct; 55(20):6089-104. PubMed ID: 20871136
[TBL] [Abstract][Full Text] [Related]
19. Effects of off-centering on dose uniformity along and around blood vessels undergoing catheter-based intravascular brachytherapy.
Nath R; Yue N
Cardiovasc Radiat Med; 2004; 5(2):88-96. PubMed ID: 15464946
[TBL] [Abstract][Full Text] [Related]
20. Monte Carlo study of radiation dose enhancement by gadolinium in megavoltage and high dose rate radiotherapy.
Zhang DG; Feygelman V; Moros EG; Latifi K; Zhang GG
PLoS One; 2014; 9(10):e109389. PubMed ID: 25275550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
